Our New White Paper on The Importance of Collection, Processing and Biopreservation Best Practices in Determining CAR-T Starting Material Quality

BioLife recently partnered with HemaCare and BioInsights to create our latest Biopreservation Best Practices White Paper. See for yourself how critical starting material quality is for CAR-T and other cell manufacturing and learn how to best optimize your biopreservation methods to follow best practices.    

Read More

BioLife Biopreservation Evidence Resources + New Citations

BioLife maintains an evidence page on our corporate website at biolifesolutions.com with links to presentations, journal articles, abstracts and posters citing the biopreservation efficacy of CryoStor and HypoThermosol.  These citation “evidence” pieces total over 345 strong and is constantly growing! Individual evidence citations (journal articles, abstracts, and posters citing our products) are searchable by title and…

Read More

Delivering a Cost Effective, Practical and Robust Cell Therapy Supply Chain

FDA approvals for  Novartis’ Kymriah™ and Kite’s Yescarta™ in 2017 ushered in a new era of medical treatments using cell and gene therapies.  Transporting these high value, unique, and often irreplaceable autologous cells from point of collection, to processing center, and back to the patient for administration calls for a paradigm change to the traditional…

Read More

Casdin Capital to Become Shareholder in BioLife Solutions – Investment Firm to Purchase Shares from Existing Holder

On April 9, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, (“BioLife” or the “Company”), announced that Casdin Capital LLC, (“Casdin”) a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company’s second…

Read More

BioLife Solutions Announces Preliminary First Quarter 2018 Revenue of $3.8 Million, up 61% Year-over-Year and 22% Sequentially 2018 Revenue Guidance Revised Upward

On April 2, 2018, BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary revenue for the three months ended March 31, 2018. First quarter 2018 preliminary revenue from sales of BioLife’s proprietary CryoStor® and HypoThermosol® biopreservation media products reached $3.8 million,…

Read More

BioLife Solutions and SAVSU Technologies to be Awarded Second Patent for Next Generation Cold Chain Technologies Designed for Cell and Gene Therapies

12 Additional Pending Patent Applications Submitted for evo® Smart Shippers, Liquid Nitrogen Dry Vapor Shippers and Cold Chain SaaS Application   On March 26, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and SAVSU Technologies, the leading developer of smart,…

Read More

BioLife Solutions CryoStor® Cell Freeze Media Highlighted in Mayo Clinic/MD Anderson Journal Article on Preservation of Patient-Derived Xenografts for Cancer Research

On March 13, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that the performance of its proprietary, cGMP CryoStor cell freeze media was reported in the journal Laboratory Investigation. In multiple comparisons of preservation efficacy of patient-derived xenograft (PDX) tumors,…

Read More